Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Primary Biliary Cholangitis Who Have an Inadequate Response or Are Intolerant to UDCA
Conditions
Interventions
Baricitinib
Placebo
Locations
12
United States
Southern California GI and Liver Centers (SCLC)
Coronado, California, United States
University of California, Davis - Health Systems
Sacramento, California, United States
University of Colorado School of Medicine
Aurora, Colorado, United States
Schiff Center for Liver Diseases/University of Miami
Miami, Florida, United States
The Institute for Digestive Health and Liver Disease at Mercy
Baltimore, Maryland, United States
Henry Ford Hospital
Detroit, Michigan, United States
Start Date
March 28, 2019
Primary Completion Date
September 26, 2019
Completion Date
September 26, 2019
Last Updated
October 14, 2020
NCT07304843
NCT07449793
NCT05749822
NCT05751967
NCT06755541
NCT07296458
Lead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions